Yumei Zhu
Biographic Data
| ID | 3932056 |
|---|---|
| NAME | Yumei Zhu |
| GIVEN NAMES | Yumei |
| FAMILY NAME | Zhu |
| SIGNATURE | ZHU Y |
| AFFILIATIONS | China Pharmaceutical University |
| ORCID | 0000-0002-5798-2901 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 24 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2017 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
A Delphi Study to Identify Priority Indicators for Formulary Selection of Innovative Anticancer Drugs in China
OBJECTIVE: To develop a multi-stakeholder, consensus-based decision support framework for prioritizing innovative anticancer drugs in Chinese hospital formularies, balancing clinical benefit, patient access, and financial sustainability. METHODS: A two-round Delphi survey was conducted with a multidisciplinary expert panel (n = 62 in Round 1; n = 51 in Round 2, 82.3% retention rate) comprising clinicians, pharmacists, health administrators, and p…
Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
Objective: To assess the economic evaluation of margetuximab plus chemotherapy over trastuzumab plus chemotherapy for women with pretreated ERBB2-positive advanced breast cancer in the United States (US) and China. Methods: Based on the SOPHIA trial, a three-state Markov model was developed to compare the cost and efficacy of margetuximab to trastuzumab for previously treated women with ERBB2-positive advanced breast cancer. The model inputs were…
Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
Background: As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) patients. However, the cost-effectiveness of this new regimen remains to be investigated. Objective: To evaluate the cost-effectiveness of camrelizumab combination therapy vs. chemotherapy for previously untreated patients with advanced, non-squamous NSCLC without Alk or Egfr gen…
Rural-urban disparities in unmet long-term care needs in China: The role of the hukou status
Rural-urban disparities in unmet long-term care needs in China: The role of the hukou status
Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
Background: As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) patients. However, the cost-effectiveness of this new regimen remains to be investigated. Objective: To evaluate the cost-effectiveness of camrelizumab combination therapy vs. chemotherapy for previously untreated patients with advanced, non-squamous NSCLC without Alk or Egfr gen…
Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
Objective: To assess the economic evaluation of margetuximab plus chemotherapy over trastuzumab plus chemotherapy for women with pretreated ERBB2-positive advanced breast cancer in the United States (US) and China. Methods: Based on the SOPHIA trial, a three-state Markov model was developed to compare the cost and efficacy of margetuximab to trastuzumab for previously treated women with ERBB2-positive advanced breast cancer. The model inputs were…
A Delphi Study to Identify Priority Indicators for Formulary Selection of Innovative Anticancer Drugs in China
OBJECTIVE: To develop a multi-stakeholder, consensus-based decision support framework for prioritizing innovative anticancer drugs in Chinese hospital formularies, balancing clinical benefit, patient access, and financial sustainability. METHODS: A two-round Delphi survey was conducted with a multidisciplinary expert panel (n = 62 in Round 1; n = 51 in Round 2, 82.3% retention rate) comprising clinicians, pharmacists, health administrators, and p…
Medicine (3 works) · Chemotherapy (2 works) · Chemotherapy regimen (2 works) · China (2 works) · Cost effectiveness (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Internal Medicine (2 works) · Oncology (2 works) · Quality-adjusted life year (2 works) · Regimen (2 works)